HELSINKI (BUSINESS WIRE) TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the first US patient has been dosed in its ovarian cancer trial (NCT05271318), using its oncolytic adenovirus, TILT-123, that has the potential to be first-in-class for this indic.
TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapies, announces that the first US patient has been dosed in its ovarian cancer trial (NCT05271318), using its
Both Meyer Turku and Rauma Marine Constructions have had to turn to the Finnish government for emergency financing, according anonymous sources interviewed by Helsingin Sanomat.
Estonian venture capital fund Trind VC raises €55 million to invest in consumer and small and medium-sized enterprise-focused startups in Europe; the fund will invest into 30-40 startups, putting more emphasis on cross-border investments in the Northern European startup ecosystem.
Paimio-based Rester has raised €6 million in growth funding. The round led by Lindström Group saw participation from Taaleri Sijoitus Oy, Besodos Investors Oy